Hammerhead ribozyme-mediated inactivation of mutant RET in medullary thyroid carcinoma

Area of Science:

• Molecular Biology
• Oncology
• Gene Therapy

Background:

• Activating mutations in the RET proto-oncogene are linked to hereditary medullary thyroid carcinoma.
• Targeting these specific mutations offers a potential therapeutic strategy.

Purpose of the Study:

• To design and evaluate a hammerhead ribozyme for selective inactivation of a transforming RET mutation (Cys634Tyr).
• To assess the therapeutic potential of ribozyme-mediated RET inhibition in preventing cancer cell transformation.

Main Methods:

• Designed a hammerhead ribozyme to cleave RET mRNA with the Cys634Tyr mutation.
• Performed in vitro RNA cleavage assays to test ribozyme specificity.
• Expressed the ribozyme in NIH/3T3 cells to evaluate its effect on RET-mediated transformation.

Main Results:

• The ribozyme selectively cleaved RET RNA harboring the Cys634Tyr mutation, sparing normal and Cys634Arg variants.
• Ribozyme expression inhibited RET-mediated colony formation in soft agar.
• Inhibition was dependent on ribozyme catalytic activity and mutation specificity.

Conclusions:

• Selective targeting of mutant RET RNA using hammerhead ribozymes is feasible.
• This strategy demonstrates potential as an effective therapeutic approach for hereditary medullary thyroid carcinoma.